ziftomenib,revumenib
kura oncology,syndax pharma
['revumenib', 'ziftomenib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'leukemia']
very impressive data with oral menin inhibitors in r/r aml w/ mll or npm1 mut presented by &amp; harry erba. this mechanism certainly looks like the most promising new wave of targeted tx for aml. interested in seeing combination strategies w/ these agents. #ash22 
Associate Prof of Med @UNC_Lineberger | Oncologist | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | Diehard NYG fan| Views my own